Clinical Trials: Isatuximab in Relapsed and Refractory Myeloma
Clinical Trials: Isatuximab in Relapsed and Refractory Myeloma image
Clinical Trials: Isatuximab in Relapsed and Refractory Myeloma
Posted Mar 22, 2018

A new CD-38 monoclonal antibody called Isatuximab (formerly known as SAR650984) is currently in Phase III clinical trials for relapsed and refractory myeloma patients. In earlier phases of isatuximab development,  "Researchers observed impressive response rates specifically among higher-risk patients who were aged older, had poor renal function and high-risk cytogenetics."

Two Phase III clinical trials are now underway:


The IKEMA study is a phase III randomized, open-label, multi-center study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma. The study will include 300 patients who have already been treated with 1-3 lines of prior myeloma therapy. Patients will be divided into two arms and will know which arm they have been assigned.

Learn More about the IKEMA Study


The IMROZ study is a phase III, randomized, open-label, multicenter study assessing the clinical benefit of isatuximab in combination with bortezomib (Velcade®), lenalidomide (Revlimid®), and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant.

To find all Isatuximab clinical trials, click here:

Find All Isatuximab Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811